Skip to main content

Advertisement

Log in

Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells

垂体腺瘤中半乳糖凝集素 −3 的表达及其与细胞凋亡关系

  • Original Article
  • Published:
Neuroscience Bulletin Aims and scope Submit manuscript

Abstract

Objective

To investigate the expressions of Galectin-3 (Gal-3), Bcl-2 and Bax in human pituitary adenomas, and to explore the interrelation among them.

Methods

RT-PCR and immunohistochemistry were applied to detect the mRNA and protein expressions of Gal-3, Bcl-2 and Bax in surgically excised human pituitary adenoma tissues, including invasive and non-invasive pituitary adenomas, and the correlation analysis was performed.

Results

The Gal-3 and Bcl-2 expressions in the invasive pituitary group were significantly higher than those in the non-invasive group, and the expression of Bax had no significant difference between the two groups. Pearson’s correlation analyses showed that the Gal-3 expression was positively correlated with Bcl-2, but was not correlated with Bax, which was inversely correlated with expression of Bcl-2.

Conclusion

Gal-3 may function through a cell death inhibition pathway involving Bcl-2 to enhance cell proliferation, which result in the invasive growth of pituitary adenoma. These results indicate that Gal-3 has an important role in pituitary tumor cell proliferation and may serves as a possible therapeutic target in treatment of pituitary tumors.

摘要

目的

探讨垂体腺瘤中半乳糖凝集素-3(Galectin-3, Gal-3)和凋亡相关基因 Bcl-2、 Bax 的内在联系。

方法

RT-PCR检测20例垂体腺瘤Gal-3、 Bcl-2和Bax mRNA的表达; 免疫组化染色检测78例垂体腺瘤中Gal-3、 Bcl-2和 Bax 蛋白表达, 分析侵袭性和非侵袭性垂体腺瘤中Gal-3、 Bcl-2 和Bax 表达的差异及其相关关系。

结果

侵袭组垂体腺瘤Gal-3和Bcl-2 mRNA和蛋白的表达水平较非侵袭组显著增高, 而Bax mRNA 和蛋白在两组中的表达水平无显著差异。 等级相关分析显示Gal-3 蛋白与Bcl-2 蛋白之间有正直线相关关系(r = 0.291, P = 0.01); Gal-3 蛋白与Bax蛋白之间无直线相关关系(r = −0.023, P > 0.05); Bcl-2 蛋白与Bax蛋白表达之间的Pearson相关系数为r = −0.267, P < 0.05(双侧), 呈负相关关系。

结论

Gal-3 可能主要是通过与Bcl-2 协同作用, 发挥其抗凋亡效应, 相对促进, 体腺瘤细胞增殖, 导致垂体腺瘤的侵袭性生长。这些结果提示Gal-3 在垂体肿瘤细胞增殖过程中发挥重要作用, 有望作为垂体腺瘤的一个治疗靶点。

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002, 1572: 263–273.

    PubMed  CAS  Google Scholar 

  2. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000, 156: 899–909.

    PubMed  CAS  Google Scholar 

  3. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002, 277: 6852–6857.

    Article  PubMed  Google Scholar 

  4. Kawatani M, Imoto M. Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion. J Biol Chem 2003, 278: 19732–19742.

    Article  PubMed  CAS  Google Scholar 

  5. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 2002, 9:103–113.

    Article  PubMed  CAS  Google Scholar 

  6. Gong JY, Shi JX, Liu CJ, Hang CH, Cheng HL, Yin HX. The role of cell proliferating nuclear antigen on predicting the recurrence of postoperative pituitary adenomas. Chin J Neurosurg 2001, 17: 11–13.

    Google Scholar 

  7. Hardy J, Vezina JL. Transsphenoidal neurosurgery of intracranial neoplasm. Adv Neurol 1976, 15: 261–273.

    PubMed  CAS  Google Scholar 

  8. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993, 33: 610–618.

    Article  PubMed  CAS  Google Scholar 

  9. Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and-9. Biochemistry 1994, 33: 14109–14114.

    Article  PubMed  CAS  Google Scholar 

  10. Yu F, Finley RL Jr, Raz A, Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome C release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 2002, 277: 15819–15827.

    Article  PubMed  CAS  Google Scholar 

  11. Raz A, Zhu DG, Hogan V, Shah N, Raz T, Karkash R, et al. Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 1990, 46: 871–877.

    Article  PubMed  CAS  Google Scholar 

  12. Schoeppner HL, Raz A, Ho SB, Bresalier RS. Expression of an endogenous galactoside-binding lectin correlates with neoplastic progression in the colon. Cancer 1995, 75: 2818–2826.

    Article  PubMed  CAS  Google Scholar 

  13. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, et al. Metastasis of human colon cancer is altered by modifying expression of the β-galactoside-binding protein galectin-3. Gastroenterology 1998, 115: 287–296.

    Article  PubMed  CAS  Google Scholar 

  14. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara E. Expression of a 31 kDa lactose-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 1994, 56: 474–480.

    Article  PubMed  CAS  Google Scholar 

  15. van den Brûle FA, Engel J, Stetler-Stevenson WG, Liu FT, Sobel ME, Castronovo V. Genes involved in tumor invasion and metastasis are differentiall y modulated by estradiol and progestin in human breast cancer cells. Int J Cancer 1992, 52: 653–657.

    Article  PubMed  Google Scholar 

  16. Nangia-Makker P, Sarvis R, Visscher DW, Bailey-Penrod J, Raz A, Sarkar FH. Galectin-3 and L1 retrotransposons in human breast carcinomas. Breast Cancer Res Treat 1998, 49: 171–183.

    Article  PubMed  CAS  Google Scholar 

  17. Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF Jr, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003, 63: 2251–2255.

    PubMed  CAS  Google Scholar 

  18. Wang H, Wang MD, Ma WB, Yang D, Shi YF, Kong YG, et al. Expression of galectin-3 in invasive prolactinomas. Acta Academia Medicinae Sinica 2005, 27: 380–381.

    Google Scholar 

  19. Jin L, Riss D, Ruebel K, Kajita S, Scheithauer BW, Horvath E, et al. Galectin-3 expression in functioning and silent ACTH-producing adenomas. Endocr Pathol 2005, 16: 107–114.

    Article  PubMed  CAS  Google Scholar 

  20. Thodou E, Argyrakos T, Kontogeorgos G. Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens) 2007, 6: 227–232.

    Google Scholar 

  21. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997, 57: 5272–5276.

    PubMed  CAS  Google Scholar 

  22. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002, 277: 6852–6857.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chui-Xue Huang  (黄垂学).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, CX., Hou, YH. & Liu, YS. Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells. Neurosci. Bull. 24, 34–38 (2008). https://doi.org/10.1007/s12264-008-1029-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12264-008-1029-y

Keywords

关键词

CLC number

Navigation